Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting

Ian K. Komenaka, Michael L. Hibbard, Chiu-Hsieh Hsu, Boo Ghee Low, Jason A. Salganick, Marcia E. Bouton, Chandra Jha

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Preoperative chemotherapy (PC) for operable breast cancer has demonstrated significant benefits in clinical trials. Many patients are treated in the community setting and some may question the applicability of PC outside the university setting. The potential benefits of PC in terms of surgical out comes in a community practice were examined. Methods: A retrospective review was performed of stage II and stage IIIA breast cancer patients from January 1, 2002 to July 31, 2009. Surgical outcomes of margin status, volume of lumpectomy, rate of lumpectomy, and re-excision lumpectomy were evaluated. Results: There were 212 patients included. Seventy-nine percent of patients who underwent PC had a clinical response and 25% had a pathologic complete response. For clinical stage T2 and stage T3 tumors, the PC group underwent lumpectomy more often than patients in the adjuvant chemotherapy (AC) group (78% versus 50%; p =.016 and 60% versus 29%; p =.015, respectively). The rate of close or positive margins in the PC group was half the rate in the AC group (23% versus 46%; p =.04) and this resulted in fewer re-excisions (p =.01). The volume of tissue removed was also smaller in the PC group (143.6 cm3 versus 273.9 cm3; p =.003).Conclusions. PC for operable breast cancer can significantly improve surgical outcomes in community-based practice.

Original languageEnglish (US)
Pages (from-to)752-759
Number of pages8
JournalOncologist
Volume16
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Community Hospital
Breast Neoplasms
Drug Therapy
Segmental Mastectomy
Adjuvant Chemotherapy
Clinical Trials

Keywords

  • Breast cancer
  • Disparities
  • Margin status
  • Minority
  • Preoperative chemotherapy
  • Re-excision
  • Surgical outcome
  • Underinsured

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting. / Komenaka, Ian K.; Hibbard, Michael L.; Hsu, Chiu-Hsieh; Low, Boo Ghee; Salganick, Jason A.; Bouton, Marcia E.; Jha, Chandra.

In: Oncologist, Vol. 16, No. 6, 06.2011, p. 752-759.

Research output: Contribution to journalArticle

Komenaka, Ian K. ; Hibbard, Michael L. ; Hsu, Chiu-Hsieh ; Low, Boo Ghee ; Salganick, Jason A. ; Bouton, Marcia E. ; Jha, Chandra. / Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting. In: Oncologist. 2011 ; Vol. 16, No. 6. pp. 752-759.
@article{7ccc2272c6914ca993f92b9392441755,
title = "Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting",
abstract = "Background: Preoperative chemotherapy (PC) for operable breast cancer has demonstrated significant benefits in clinical trials. Many patients are treated in the community setting and some may question the applicability of PC outside the university setting. The potential benefits of PC in terms of surgical out comes in a community practice were examined. Methods: A retrospective review was performed of stage II and stage IIIA breast cancer patients from January 1, 2002 to July 31, 2009. Surgical outcomes of margin status, volume of lumpectomy, rate of lumpectomy, and re-excision lumpectomy were evaluated. Results: There were 212 patients included. Seventy-nine percent of patients who underwent PC had a clinical response and 25{\%} had a pathologic complete response. For clinical stage T2 and stage T3 tumors, the PC group underwent lumpectomy more often than patients in the adjuvant chemotherapy (AC) group (78{\%} versus 50{\%}; p =.016 and 60{\%} versus 29{\%}; p =.015, respectively). The rate of close or positive margins in the PC group was half the rate in the AC group (23{\%} versus 46{\%}; p =.04) and this resulted in fewer re-excisions (p =.01). The volume of tissue removed was also smaller in the PC group (143.6 cm3 versus 273.9 cm3; p =.003).Conclusions. PC for operable breast cancer can significantly improve surgical outcomes in community-based practice.",
keywords = "Breast cancer, Disparities, Margin status, Minority, Preoperative chemotherapy, Re-excision, Surgical outcome, Underinsured",
author = "Komenaka, {Ian K.} and Hibbard, {Michael L.} and Chiu-Hsieh Hsu and Low, {Boo Ghee} and Salganick, {Jason A.} and Bouton, {Marcia E.} and Chandra Jha",
year = "2011",
month = "6",
doi = "10.1634/theoncologist.2010-0268",
language = "English (US)",
volume = "16",
pages = "752--759",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting

AU - Komenaka, Ian K.

AU - Hibbard, Michael L.

AU - Hsu, Chiu-Hsieh

AU - Low, Boo Ghee

AU - Salganick, Jason A.

AU - Bouton, Marcia E.

AU - Jha, Chandra

PY - 2011/6

Y1 - 2011/6

N2 - Background: Preoperative chemotherapy (PC) for operable breast cancer has demonstrated significant benefits in clinical trials. Many patients are treated in the community setting and some may question the applicability of PC outside the university setting. The potential benefits of PC in terms of surgical out comes in a community practice were examined. Methods: A retrospective review was performed of stage II and stage IIIA breast cancer patients from January 1, 2002 to July 31, 2009. Surgical outcomes of margin status, volume of lumpectomy, rate of lumpectomy, and re-excision lumpectomy were evaluated. Results: There were 212 patients included. Seventy-nine percent of patients who underwent PC had a clinical response and 25% had a pathologic complete response. For clinical stage T2 and stage T3 tumors, the PC group underwent lumpectomy more often than patients in the adjuvant chemotherapy (AC) group (78% versus 50%; p =.016 and 60% versus 29%; p =.015, respectively). The rate of close or positive margins in the PC group was half the rate in the AC group (23% versus 46%; p =.04) and this resulted in fewer re-excisions (p =.01). The volume of tissue removed was also smaller in the PC group (143.6 cm3 versus 273.9 cm3; p =.003).Conclusions. PC for operable breast cancer can significantly improve surgical outcomes in community-based practice.

AB - Background: Preoperative chemotherapy (PC) for operable breast cancer has demonstrated significant benefits in clinical trials. Many patients are treated in the community setting and some may question the applicability of PC outside the university setting. The potential benefits of PC in terms of surgical out comes in a community practice were examined. Methods: A retrospective review was performed of stage II and stage IIIA breast cancer patients from January 1, 2002 to July 31, 2009. Surgical outcomes of margin status, volume of lumpectomy, rate of lumpectomy, and re-excision lumpectomy were evaluated. Results: There were 212 patients included. Seventy-nine percent of patients who underwent PC had a clinical response and 25% had a pathologic complete response. For clinical stage T2 and stage T3 tumors, the PC group underwent lumpectomy more often than patients in the adjuvant chemotherapy (AC) group (78% versus 50%; p =.016 and 60% versus 29%; p =.015, respectively). The rate of close or positive margins in the PC group was half the rate in the AC group (23% versus 46%; p =.04) and this resulted in fewer re-excisions (p =.01). The volume of tissue removed was also smaller in the PC group (143.6 cm3 versus 273.9 cm3; p =.003).Conclusions. PC for operable breast cancer can significantly improve surgical outcomes in community-based practice.

KW - Breast cancer

KW - Disparities

KW - Margin status

KW - Minority

KW - Preoperative chemotherapy

KW - Re-excision

KW - Surgical outcome

KW - Underinsured

UR - http://www.scopus.com/inward/record.url?scp=79959619270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959619270&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2010-0268

DO - 10.1634/theoncologist.2010-0268

M3 - Article

C2 - 21558133

AN - SCOPUS:79959619270

VL - 16

SP - 752

EP - 759

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 6

ER -